Double-blind Abatacept — Competitive Intelligence Brief

Double-blind Abatacept (Double-blind Abatacept) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CTLA-4 fusion protein (T-cell co-stimulation inhibitor). Area: Immunology.

phase 3 CTLA-4 fusion protein (T-cell co-stimulation inhibitor) CD80, CD86 Immunology Small molecule

Target snapshot

Double-blind Abatacept (Double-blind Abatacept) — Bristol-Myers Squibb. Abatacept is a fusion protein that blocks T-cell co-stimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and reducing inflammatory responses.

Comparator set (4 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Double-blind Abatacept TARGET	Double-blind Abatacept	Bristol-Myers Squibb	phase 3	CTLA-4 fusion protein (T-cell co-stimulation inhibitor)	CD80, CD86
Orencia	abatacept	Bristol-Myers Squibb	marketed	Selective T cell costimulation modulator	CD80, CD86, CD28	2005-01-01
Placebo matching with Abatacept	Placebo matching with Abatacept	Bristol-Myers Squibb	marketed	CTLA-4 fusion protein; T-cell costimulation inhibitor	CD80, CD86
Abatacept SC	Abatacept SC	University Medical Center Groningen	phase 3	Costimulation modulator; T cell inhibitor	CD80, CD86
Intravenous (IV) abatacept	Intravenous (IV) abatacept	Bristol-Myers Squibb	phase 3	CTLA-4 fusion protein; T-cell costimulation inhibitor	CD80, CD86

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CTLA-4 fusion protein (T-cell co-stimulation inhibitor) class)

1. Bristol-Myers Squibb · 1 drug in this class